

Significance of headache in inflammatory bowel diseases

Baqir Ali Khalid¹, Bilal Ali², Muhammad Nauman Shah³, Muhammad Asjad Saleem²,

Khadija Mohib², Ehtisham Alam⁴, Sangeen Khan Wazir⁵

1. Foundation University Islamabad Campus, Pakistan
2. Dow Medical College, Karachi, Pakistan
3. Bannu Medical College, Pakistan
4. Pakistan Institute of medical sciences, Pakistan
5. Khyber Medical college, Pakistan

Abstract

Introduction: Research has shown clear correlation between inflammatory conditions and a prothrombotic state. Cerebral vein thrombosis can be fatal and diagnosis is challenging as symptoms are unspecific. **Objectives:** The main objective of the study is to find the association between headache and inflammatory bowel diseases. **Material and methods:** This cross-sectional study was conducted in Foundation University Islamabad and Dow Medical College Karachi during 2021 to 2022. Data was collected from 20 patients presenting in OPD of the hospital. Patients with inflammatory bowel disease unclassified presented to emergency department with a 3-day history of nausea, vomiting, headache and sporadic abdominal pain along with intermittent bloody stools in recent weeks. **Results:** Data was collected from 20 patients. There were 8 males and 12 females with mean age of 45.67 ± 2.34 years. No differences were found when comparing the distribution of data including IBD and migraine or severe headache. The prevalence of migraine or severe headache and 95% confidence intervals (CIs) and by selected characteristics were calculated. **Conclusion:** It is concluded that headache is frequent and disabling in IBD patients, highlighting the probable role of the brain-gut axis in this co-occurrence of pathologies.

Introduction

Research has shown clear correlation between inflammatory conditions and a prothrombotic state. Cerebral vein apoplexy can be deadly and finding is trying as side effects are vague. The rate of constant provocative gut infection is expanding joined with a pattern towards

more youthful age at show [1]. In this way, a raise of the entanglement rate is normal and thus we might want to make different clinicians cautious by stressing the difficulties we experienced to make the determination of cerebral vein apoplexy and revealing the mistakes a few experienced clinical groups made en route. We might want to urge clinicians to continually reexamine their choices, particularly in the event that there is nonappearance of clinical improvement after a generally deep rooted treatment [2].

The pervasiveness of extraintestinal appearances (EIMs) goes from 6% to 40% in provocative entrail sickness (IBD) in which numerous organs including joints, skin, eyes, and hepatobiliary framework were involved [3]. A portion of the EIMs are connected with infection action. EIMs address the primary driver of horribleness in Compact disc. In provocative gut illnesses, numerous neurological entanglements, including migraine, may happen as EIMs, and they are considered to have a commonness going from 0.2% to 47.5% [4]. Nonetheless, those difficulties may frequently go clinically undiscovered or potentially the conclusion might be postponed. The specific etiology of migraine and other neurological confusions in Cd remaining parts obscure, yet speculatively many elements, including resistant intervened peculiarities, nourishing shortages, prothrombotic conditions, and utilization of drugs, have been suggested [5].

IBD pervasiveness in France is around 1-2/1000, tantamount to the remainder of western Europe and North America. Albeit continuous, not very many examinations have zeroed in on the study of disease transmission and results of constant agony in these pathologies. Furthermore, two cross-sectional examinations have shown an expansion in cerebral pain pervasiveness, and especially headache migraines, in IBD patients [6]. In the last option study, the chances proportion was 2.66 (95% certainty stretch = 1.08-6.54) contrasted with everybody. In any case, the review was not planned explicitly to search for headache pervasiveness in the IBD populace and the predominance of headache in the benchmark

group was strikingly low with just 6%, though headache commonness in enormous epidemiological examinations is somewhere around 14% in occidental nations [7].

Concerning torment with neuropathic qualities (NCs), there are no information in IBD patients and the predominance of neuropathy in IBD stays dubious. As neuropathic torment seriously influences personal satisfaction and legitimizes explicit medicines, it appears to be vital to be aware on the off chance that some IBD patients ought to profit from such medicines [8]. IBD is a lifetime foundational jumble that might exhibit comparable previously mentioned epidemiological qualities of headache or extreme migraine, for example, being bound to be first analyzed among kids or youthful grown-ups and bound to co-happen with other persistent circumstances including asthma, sorrow or nervousness, cerebral pain, and other neurological problems. Until now, the relationship of headache with IBD has been accounted for just in clinically based research with small examples [9].

Objectives

The main objective of the study is to find the association between headache and inflammatory bowel diseases.

Material and methods

This cross-sectional study was conducted in Foundation University Islamabad and Dow Medical College Karachi during 2021 to 2022. Data was collected from 20 patients presenting in OPD of the hospital. Patients with provocative entrail illness unclassified gave to crisis division a 3-day history of sickness, retching, migraine and irregular stomach torment alongside discontinuous ridiculous stools as of late. Their pancolitis was analyzed year and a half prior. They treated with sulfasalazine and three courses of steroids up until this point and current drug was azathioprine. The earlier weeks, their provocative markers were typical. Two days before show, they contact with youngsters impacted by

gastroenteritis. Aside from slight stomach delicacy, the clinical assessment was mediocre. Blood tests upon the arrival of affirmation showed a C-reacting protein of 86 mg/L, a typical white platelet count and lack of iron frailty (hemoglobin 110 g/L). Other lab discoveries like liver and pancreas chemicals, creatinine, urea and electrolytes were ordinary. Egg whites was low (26 g/L) as it was during earlier weeks. The functioning determination was 'flare of fiery entrail infection' with cerebral pain remembered to be optional to dynamic sickness and thus they got a first portion of infliximab (5 mg/kg) as her provocative inside illness had become impervious to steroids and azathioprine. An endoscopy to reconsider degree of sickness was dropped because of calculated issues and considering assumed unfortunate reaction to the primary infliximab implantation, they got a second portion of infliximab (10 mg/kg). Resulting endoscopy uncovered indications of constant instead of intense irritation. The patients got anticoagulation and further clinical administration, at the end of the day required a ventriculoperitoneal shunt for viable side effect control. Generally speaking, it required 3 weeks from beginning show to determination. With the exception of cerebral pain and queasiness, the patients never had some other neurological side effects. The patients has no family background of apoplexy or prothrombotic conditions. To ensure a maximal response rate, the questionnaire was deliberately simple, and it was designed to be completed in less than 15 min. Validated questionnaires were used to limit the risk of bias.

Results

Data was collected from 20 patients. There were 8 males and 12 females with mean age of 45.67 ± 2.34 years. No differences were found when comparing the distribution of data including IBD and migraine or severe headache. The prevalence of migraine or severe headache and 95% confidence intervals (CIs) and by selected characteristics were calculated.

Table 01: Demographic factors in selected patients (n=20)

Characteristics	IBD (95% CI)	No IBD (95% CI)
Smoking status		
Current smoker	17.8 (14.7-21.3)	15.3 (14.9-15.8)
Former smoker	30.4 (26.3-34.8)	21.9 (21.5-22.4)
Non-smoker	51.9 (47.5-56.2)	62.8 (62.1-63.4)
Body mass index (BMI, kg/m ²)		
Non-obese (BMI < 30.0)	69.2 (64.8-73.2)	70.1 (69.6-70.7)
Obese (BMI ≥ 30.0)	30.8 (26.8-35.2)	29.9 (29.3-30.4)
Serious psychological distress		
Yes	65.6 (60.8-70.0)	42.0 (41.4-42.6)
No	34.4 (30.0-39.2)	58.0 (57.4-58.6)
Yes	8.1 (5.7-11.3)	3.5 (3.2-3.7)
No	91.9 (88.7-94.3)	96.5 (96.3-96.8)

The overall age-adjusted prevalence of migraine or severe headache was 15.4% (n = 9,062) and of IBD was 1.2% (n = 862). Participants with IBD reported a higher age-adjusted prevalence of migraine or severe headache than those without IBD.

Table 02: Association of IBD with Migraine or severe headache

Migraine or severe headache	IBD (95% CI)	No IBD (95% CI)
Yes	27.2 (23.1-31.7)	14.8 (14.4-15.2)
No	72.8 (68.3-76.9)	85.2 (84.8-85.6)

Discussion

Among pain symptoms, the most frequent were headaches including migraine which concerned 41% of this cohort, i.e. twice more than in the general population of equivalent age. As recently portrayed, headache was related with a more youthful age, female orientation and higher despondency [10]. The predominance of headache in IBD patients has been accounted for somewhere close to 10% and 30% reflecting contrasts in concentrate on plan and patient choice [11]. Of these two examinations, one was not planned explicitly to

search for headache pervasiveness in the IBD populace and incorporated a benchmark group with a strikingly low headache predominance and both were underpowered to reach firm determinations [12]. Subsequently, our review is the principal showing the high predominance of headache in an obvious partner of IBD patients. Likewise, our survey to distinguish headache was more exact than the three inquiries of the ID-headache test that can be utilized for screening, however doesn't permit a precise conclusion. Our review called attention to that headache could exceptionally influence 30% of the patients' personal satisfaction [13]. Nonetheless, efficient screening isn't prescribed to date, as headache isn't considered as an EIM up until this point, albeit this co-occurrent side effect is undeniably more incessant than joint inclusion, which is viewed as the most successive EIM [14].

The connection among headache and IBD stays obscure up to this point. The pathophysiology of headache isn't totally perceived, both neuronal and vascular components being involved. It has recently been proposed in patients with various sclerosis that aggravation could increment headache risk [15]. As IBD is a constant fiery sickness, we speculate the conceivable ramifications of the mind stomach hub in the turn of events or potentially upkeep of headache. The freedom of supportive or provocative cytokines in the circulatory system could likewise be a method for leaning toward headache cerebral pains. As we showed that headache isn't connected with IBD clinical movement, we could consider headache as an EIM which could have an independent development [16].

Conclusion

It is concluded that headache is frequent and disabling in IBD patients, highlighting the probable role of the brain–gut axis in this co-occurrence of pathologies.

References

1. Orfei, Martina; Gasparetto, Marco; Torrente, Franco (2019). *Headache and inflammatory bowel disease: think cerebral vein!*. *BMJ Case Reports*, *12*(1), e227228-. doi:10.1136/bcr-2018-227228
2. Moisset, X.; Bommelaer, G.; Boube, M.; Ouchchane, L.; Goutte, M.; Dapoigny, M.; Dallel, R.; Guttman, A.; Clavelou, P.; Buisson, A. (2017). *Migraine prevalence in inflammatory bowel disease patients: A tertiary-care centre cross-sectional study*. *European Journal of Pain*, (), -. doi:10.1002/ejp.1056
3. Clarke, S., Weinberg, D. & Limdi, J.K. Importance of headache in inflammatory bowel disease. *Indian J Gastroenterol* **41**, 417–418 (2022). <https://doi.org/10.1007/s12664-021-01193-5>
4. Yong Liu;Fang Xu;Anne G. Wheaton;Kurt J. Greenlund;Craig W. Thomas; (2021). *The association between inflammatory bowel disease and migraine or severe headache among US adults: Findings from the National Health Interview Survey, 2015–2016* . *Headache: The Journal of Head and Face Pain*, (), – . doi:10.1111/head.14087
5. National Center for Health Statistics. Variance Estimation Guidance, NHIS 2016-2017 (Adapted from NHIS Survey Description Documents); October, 2018. <https://www.cdc.gov/nchs/data/nhis/2016var.pdf>
6. Drossman DA, Hasler WL. Rome IV-functional GI disorders: disorders of gut-brain interaction. *Gastroenterology*. 2016;150(6):1257-1261.
7. Ashina M, Hansen JM, Do TP, Melo-Carrillo A, Burstein R, Moskowitz MA. Migraine and the trigeminovascular system-40 years and counting. *Lancet Neurol*. 2019;18(8):795-804.
8. Kristiansen HA, Kvaerner KJ, Akre H, Overland B, Russell MB. Migraine and sleep apnea in the general population. *J Headache Pain*. 2011;12(1):55-61.

9. Cognat E, Crassard I, Denier C. Cerebral venous thrombosis in inflammatory bowel diseases: eight cases and literature review. *Int J Stroke*. 2011;6:487–92.
10. Wetzel SG, Kirsch E, Stock KW. Cerebral veins: comparative study of CT venography with intraarterial digital subtraction angiography. *Am J Neuroradiol*. 1999;20:249–55.
11. Stam J. Thrombosis of the cerebral veins and sinuses. *N Engl J Med*. 2005;352:1791–8.
12. Silverberg, M.S., Satsangi, J., Ahmad, T., Arnott, I.D.R., Bernstein, C.N. et al. (2005). Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. *Can J Gastroenterol* 19 (Suppl A), 5A–36A.
13. Vavricka, S.R., Schoepfer, A., Scharl, M., Lakatos, P.L., Navarini, A., Rogler, G. (2015). Extraintestinal manifestations of inflammatory bowel disease. *Inflamm Bowel Dis* 21, 1982–1992.
14. Harris, P.A., Taylor, R., Thielke, R., Payne, J., Gonzalez, N., Conde, J.G. (2009). Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform* 42, 377–381.
15. Katsanos AH, Katsanos KH, Kosmidou M, et al. Cerebral sinus venous thrombosis in inflammatory bowel diseases. *QJM* 2013;106:401–13

